Geographic atrophy
Geographic atrophy Market

Geographic Atrophy (GA) is a chronic progressive degeneration of the macula due to late-stage age-related macular degeneration (AMD). GA is a progressive, irreversible, and blinding disease that tends to affect both eyes. Nearly two-thirds of geographic atrophy cases are reported in people aged 80 years and above.


Geographic Atrophy Epidemiological Segmentation 

The Epidemiological Segmentation of Geographic Atrophy in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Cases of Geographic Atrophy
  • Total Diagnosed cases of Geographic Atrophy
  • Total Diagnosed cases of Geographic Atrophy by Age Distribution
  • Total Geographic Atrophy Cases by Visual Impairment
  • Treated cases of Geographic Atrophy


Geographic Atrophy Epidemiology 

  • The total diagnosed cases of Geographic Atrophy in 7MM in 2017 was 2,516,401
  • The total treated cases of Geographic Atrophy in 7MM in 2017 was 1,162,112


Geographic Atrophy Market

Market Size of Geographic Atrophy in 7MM in 2017 was USD 276 million


Geographic Atrophy Market Drivers

  • Increasing prevalence rate
  • Emerging novel treatment options
  • Patient-friendly Dosage Regimes


Geographic Atrophy Market Barriers

  • Failure of Investigational Drugs
  • Limited knowledge of Geographic Atrophy
  • Lack of access to specialists
  • Lack of focus on visual restoration
  • Compliance and Adherence


Geographic Atrophy Emerging Drugs

The emerging drugs of the Geographic Atrophy market are 

  • Pegcetacoplan (APL-2)
  • Zimura (avacincaptad pegol)
  • ALK-001
  • HMR59 (AAVCAGsCD59)
  • Risuteganib
  • ElamipretideGT005
  • CPCB-RPE1
  • RO7171009 (RG6147)
  • IONIS-FB-LRx
  • OpRegen
  • Palucorcel (CNTO 2476)

 And many others.  

 

Geographic Atrophy Key Players

The key players in the Geographic Atrophy market are

  • Apellis Pharmaceuticals
  • Iveric Bio (formerly Ophthotech Corporation
  • Alkeus Pharmaceuticals
  • Hemera Biosciences
  • Allegro Ophthalmics
  • Stealth BioTherapeutics
  • Gyroscope Therapeutics
  • Regenerative Patch Technologies
  • Roche (Genentech
  • Ionis Pharmaceuticals/Roche
  • CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
  • Janssen Research & Development

 And many others.